Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) March 6, 2006


Interpharm Holdings, Inc.
(Exact name of Registrant as specified in charter)

Delaware
0-22710
13-3673965
(State or other jurisdiction of incorporation)
(Commission File Number)
 (IRS Employer Identification No.)
     
      
75 Adams Avenue, Hauppauge, New York 11725
(Address of principal executive offices)   (Zip Code)

Registrant's telephone number, including area code: (631) 952-0214

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
 
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 



Item 5.02  Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Effective March 6, 2006, Dr. Mark A. Goodman resigned from his position as a member of the registrant’s Board of Directors.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
 
INTERPHARM HOLDINGS, INC.
 
 		  
 		  
 
March 8, 2006
 By:  
/s/ George Aronson                                   
 
George Aronson
 
Chief Financial Officer

 
 
Exhibits
 
Exhibit 17  Letter from Dr. Mark A. Goodman M.D. dated March 6, 2006